ATMI LifeSciences specialises in single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries.
“This acquisition immediately strengthens our offering and broadens our already extensive portfolio of advanced solutions for biopharmaceutical customers,” said Pall chairman and CEO Larry Kingsley.
ATMI CEO Doug Neugold added: “We are very happy to have Pall as the new owner of this business, and believe the fit and their capabilities will accelerate its growth and provide great support to our customers.”